A question for sponsors

What if your most valuable insight is already in your data?

Every trial holds more knowledge than is ever published.

SIROai surfaces hidden insights across clinical, imaging, real-world and patient data — turning finished studies into new evidence.

Clinical Trials Real-World Evidence Post-Marketing Surveillance Patient Intelligence
The opportunity Sponsors spend years and millions generating data — most of it analyzed only once.

Every study has more to say.


The opportunity is not always to collect more data — it is to learn more from the data you already have.

Unexplored subgroups, unanalyzed endpoints, signals buried in imaging and text, patient experience that never reached the protocol — most of it stays undiscovered.

SIROai connects every dimension of evidence to surface new perspectives within studies you have already run.

A completed trial isn't the end of discovery — it's the start.

Data dissolving and resolving into insight

From data you already hold to insight you don’t yet know.

How SIROai helps Four dimensions of evidence, one connected view.

Clinical Data

Unexplored relationships, outcomes and subgroups inside data you've already collected.

Imaging Data

Deeper signal from radiology and pathology through structured central review.

Real-World Data

Extend study value with longitudinal, real-world evidence.

Patient Voice

Treatment experiences, unmet needs and real-world perspectives at scale.

From data to discovery From one existing study.
+New publication opportunities
+Real-world evidence generation
+Additional scientific analyses
+Post-marketing intelligence
+Novel patient subgroup insights
+Clearer view of treatment journeys
The platform OUR VISION

Introducing ctOS — the Clinical Trials Operating System.

One operating system for the modern trial — central imaging reads, the voice of the patient and registry studies, connected and compliant.

Central Reporting Viewer

Read, report and adjudicate every image in one place.

Unified viewer for whole-slide pathology and DICOM radiology, with blinded central reads.

HistopathologyDICOM21 CFR Part 11

Voice of Patient Analysis

Hear what patients say when no one is asking.

Surfaces sentiment, unmet needs and early safety signals from social conversations.

RedditYouTubeInstagram (soon)

Registry Platform

Run registry studies end to end.

Design and run registries at scale, powered by next-gen OCR that digitises source documents.

Next-gen OCRStudy builderFollow-up

CSR Mining

Uncover what your finished studies already know.

Mines existing study reports for unexplored endpoints, subgroups and signals.

CSR analysisSecondary insightsExisting data
One Platform. Every Study.
Built for regulated research

Compliance is not a feature. It is the foundation.

21 CFR Part 11
Validated for regulated research from the ground up.
Audit Trails
Every action captured in a complete, immutable history.
Electronic Signatures
Attributable, secure sign-off across every module.
Role-Based Access
Granular permissions across the platform.
Who we are Five years building clinically validated AI — and the regulatory discipline behind it.

We know what clinical-grade AI truly takes.

SIROai has spent five years building and deploying clinically validated diagnostic AI for hospitals and pathology labs — from Pap smear screening to cancer diagnosis on histopathology. That taught us the regulatory rigor every algorithm needs before it reaches a patient.

Built & validated Clinical AI built for hospitals and pathology labs.
I

AI-assisted Pap smear

Cervical cytology screening for faster, more consistent review.

II

Lung cancer diagnosis

Malignancy detection from histopathology whole-slide specimens.

III

GI cancer diagnosis

Gastrointestinal cancer identification for confident reporting.

Leadership
Rushabh Mehta, CEO of SIROai

Rushabh Mehta

Chief Executive Officer

Rushabh is a customer-focused business leader with over 10 years of experience in the AI and analytics industry. Throughout his career, he has worked with organizations across sectors to harness the power of data, analytics, and artificial intelligence to drive operational excellence, improve decision-making, and accelerate business growth. As CEO, Rushabh is responsible for defining the company's strategic vision, driving innovation, and ensuring the delivery of high-impact solutions that create measurable value for clients. Under his leadership, the company continues to expand its AI and analytics capabilities, helping organizations navigate digital transformation and unlock sustainable competitive advantages in an increasingly data-driven world.